1. Introduction {#sec1}
===============

Glutathione S-transferases (GSTs) are a superfamily of multifunctional isoenzymes involved in the cellular detoxification of several endogenous and exogenous compounds. GSTs catalyze the nucleophilic attack of glutathione (GSH) on the electrophilic centers of substrates, including insecticides, toxic compounds, metabolites, and organic hydroperoxides. GSTs play a crucial role against carcinogens, therapeutic drugs, and various types of cellular oxidative damage \[[@B1]\]. GSTs also regulate the biosynthesis and intracellular transport of hormones \[[@B1]\]. Based on their sequence similarity and substrate specificities, GSTs are subdivided into at least ten subfamilies: alpha, delta, epsilon, kappa, mu, pi, sigma, theta, zeta, and omega \[[@B2]\].

The omega class GST (GSTO) is the most recently defined GST class and a relatively ancient cytosolic enzyme \[[@B3], [@B4]\]. GSTOs appear to be widespread in nature and have been identified in bacteria, insects, yeast, mammals, and plants \[[@B2], [@B3], [@B5]--[@B7]\]. GSTO shares low sequence similarity with other GST classes but exhibits the GST fold. GSTO has interesting characteristics compared with those of other GST types. The active sites of GSTOs have a cysteine residue at the N-terminus that can bind to GSH, whereas other GST classes have tyrosine or serine residues in their active sites \[[@B8]\]. GSTOs have distinct enzymatic properties and thiol transferase and dehydroascorbate (DHA) reductase activities, which are similar to reactions catalyzed by thioredoxin and glutaredoxin \[[@B3]\]. There is increasing evidence that GSTOs are also involved in the detoxification of several exogenous stressors. Silkmoth GSTO was induced in the fat body after exposure to several environmental stressors, including bacteria and ultraviolet-B (UV-B) \[[@B9]\]. GSTO3 from the human pathogenic filarial worm *Onchocerca volvulus* (*Ov*GSTO3) demonstrates stress-resistant effects \[[@B10]\]. Overexpressing GSTO-1 in *Caenorhabditis elegans* exhibits increased resistance during oxidative damage \[[@B11]\]. In addition, GSTOs were shown to scavenge free radicals by regulating DHA reduction and catalyzing the reduction of inorganic arsenic, monomethylarsonate (MMA), and dimethylarsonate (DMA) \[[@B12]--[@B14]\]. *In vitro* studies have shown that human GSTO1 participates in modulation of the ryanodine receptor, which is a Ca^2+^ release channel. In addition, these studies also showed that human GSTO1 is involved in modulation of the signaling pathway during c-Jun N-terminal kinase- (JNK-) mediated apoptosis and in the activation of interleukin-1*β*, an important mediator of inflammatory response \[[@B15]--[@B17]\]. Human GSTO1-1 is a novel regulator of lipopolysaccharide- (LPS-) induced inflammatory responses in macrophages and is required for LPS-mediated signaling in macrophages \[[@B18], [@B19]\].

Recently, an important role for human GSTO1-1 in glutathionylation of the target proteins has been described \[[@B17], [@B20]\]. *β*-Actin has been reported to be deglutathionylation by human GSTO1-1 \[[@B20]\]. GSTO1-1 decreased global protein glutathionylation level in macrophages \[[@B18]\]. These findings indicate a critical role for GSTO1 in redox homeostasis through affecting glutathionylation/deglutathionylation of the target proteins. Furthermore, genetic polymorphisms in the human *GSTO1* and *GSTO2* genes may be associated with the risk of bladder, urothelial, breast, and ovarian cancer \[[@B21], [@B22]\]. Thus, GSTOs play important roles in decreasing oxidative stress produced by various stressors and cellular processes. Recent studies related to neurodegenerative disorders have implicated polymorphic variants of GSTOs in the age at onset and progression of neurodegenerative diseases such as Alzheimer\'s disease (AD) and Parkinson\'s disease (PD) \[[@B23]--[@B25]\]. GSTO2 expression levels are decreased in the brains of AD patients. Although GSTO has a protective function against neuronal damage, the molecular mechanisms and physiological functions of GSTOs are still not clear and should be researched further. In this review, we mainly focus on recent studies that have investigated the neuroprotective functions of GSTOs in the *Drosophila* model system.

2. Omega Class Glutathione S-Transferases in *Drosophila* {#sec2}
=========================================================

On the basis of the genome sequences and comparative analyses, the *Drosophila* GST genes can be divided into six subfamilies: delta, epsilon, sigma, omega, zeta, and theta. *Drosophila* harbors 36 GST genes that encode 41 proteins \[[@B2], [@B26]\]. Four different *GSTO* genes in *Drosophila* are located on chromosome 3L. *GSTO* genes form a cluster spanning approximately 6 kb \[[@B2]\]. This is evidence of internal duplication within the cluster, evolutionally. This duplication gave rise to differentially expressed GSTO isoforms and generated diverse members with differing functionality. These four *GSTO* genes had been named previously as follows: *sepia*, *GstO1*, *GstO2*, and *GstO3* \[[@B2]\]. The sequence identities/similarities are high, at 43--65%/66--82%, based on the amino acid sequence alignment of the different isoforms of GSTO in *Drosophila* \[[@B27]\]. All isoforms of GSTO have N-terminal extensions and cysteine residues in the active site rather than tyrosine or serine residues, which are found in the active sites of other classes of GSTs. Furthermore, all isoforms of GSTOs have high thiol transferase and DHA reductase activities, characteristic of GSTOs, and low activity toward 1-chloro-2,4-dinitrobenzene (CDNB), a general GST substrate \[[@B27]\]. In addition, the tissue distributions of GSTOs were determined by reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis \[[@B27]--[@B29]\]. They have a different tissue distribution in *Drosophila*. Sepia was found only in the eye. GstO1 and GstO2A were highly expressed in the head and abdomen of adult flies. However, GstO2B and GstO3 were expressed at approximately the same level in all tissues. Therefore, these studies suggest that *Drosophila* GSTOs might possess tissue-specific physiological functions.

3. Neuroprotective Functions of GstOs in *Drosophila* {#sec3}
=====================================================

3.1. GstO1 Has a Protective Function against Neuronal Toxicity {#sec3.1}
--------------------------------------------------------------

Oxidative stress poses a major threat to organisms living in an aerobic environment and plays a critical role in several neurological disease processes \[[@B30]\]. Oxidative stress is widely implicated in neuronal cell death. Hydrogen peroxide (H~2~O~2~) has been implicated in triggering apoptotic death in several cell types \[[@B31], [@B32]\]. It may also induce the production of reactive oxygen species (ROS) in neuronal cells. In a recent study, our group determined that GstO1 is highly expressed in the head, and *GstO1* mutant flies are sensitive to ROS, produced under H~2~O~2~ exposure. Interestingly, H~2~O~2~-induced lethality and apoptotic cell death of neurons in *GstO1* mutant flies were suppressed by neuron-specific expression of GstO1. These results suggest that GstO1 has a physiological function in neurons, and GstO1 neuronal expression is sufficient to suppress H~2~O~2~-induced neurotoxicity in *GstO1* mutant flies.

Phosphorylation cascades leading to the activation of MAPK, including ERK, JNK, and p38, are among the major cellular signaling pathways known to influence cell survival under ROS damage \[[@B33]--[@B35]\]. Several reports have shown that accumulation of ROS in response to H~2~O~2~ exposure results in the activation of several stress kinases, involving the ASK1, ERK, and JNK pathways \[[@B33]--[@B35]\]. Our studies of H~2~O~2~-induced neurotoxicity in *GstO1* mutant flies reveal that increased ERK phosphorylation in *GstO1* mutant flies treated with H~2~O~2~ was rescued by the expression of GstO1 \[[@B28]\]. The mechanism for the suppression of H~2~O~2~-mediated neurotoxicity appears to be mediated through the suppression of ERK pathway activation. Thus, these findings strongly demonstrate that GstO1 has a critical, protective role against H~2~O~2~-mediated neurotoxicity by regulating the MAPK pathway.

3.2. GstO2 Regulates Complex V Activity in Neurodegenerative Disease {#sec3.2}
--------------------------------------------------------------------

Previous studies have reported that single-nucleotide polymorphisms in human *GSTO* genes are associated with the age at onset for AD, PD, and stroke \[[@B36], [@B37]\]. The *GSTO1 D140* allele is associated with a decreased risk of familial PD \[[@B23]\]. In addition, a possible relationship between GSTOs loci and the age at onset of amyotrophic lateral sclerosis (ALS) has been reported \[[@B38]\]. These various studies provide evidence that genetic variation of human *GSTOs* can influence the age at onset of several different neurodegenerative diseases. These studies also suggest that GSTOs may contribute to the pathogenesis of each neurological disorder and have a protective role in neuronal cells during the development of neurological diseases. However, many studies have failed to demonstrate the molecular function of GSTOs *in vivo*. A speculative mechanism involving the pathogenesis of neurodegenerative disease was recently proposed. Our subsequent study showed that GstO2A is a novel genetic regulator of the *Drosophila parkin* mutant, which is the popular *Drosophila* model of PD \[[@B39]\]. Furthermore, we showed compelling evidence that GstO2A catalyzes the glutathionylation of the ATP synthase *β* subunit, which is a catalytic component of the mitochondrial ATP synthase complex (complex V). The glutathionylation of the ATP synthase *β* subunit induced by GstO2A expression in *parkin* mutants is important for the rescue of ATP synthase activity in these mutants \[[@B39]\]. Moreover, human GSTO1 has the capacity to glutathionylate or deglutathionylate target proteins \[[@B20]\]. Although the role GstO2A plays in the glutathionylation of target proteins is not clear, these findings strongly suggest that enhancing the activity of GstO2A in neuronal cells could alleviate neurodegeneration in the *Drosophila* model of PD.

3.3. GstO2 Regulates Ascorbic Acid Recycling {#sec3.3}
--------------------------------------------

Ascorbic acid (AsA), the reduced form of vitamin C, is an essential cofactor in various enzymatic reactions. AsA is an important antioxidant with multiple cellular functions and plays a role in detoxification against endogenous and exogenous stressors. Interestingly, the brain exhibits one of the highest AsA concentrations in the body. AsA concentrations of 1\~2 mM have been detected throughout the brain while intracellular concentrations in neuronal cells are much higher, reaching up to 10 mM \[[@B14]\]. This evidence suggests a critical role of AsA in the brain or neuronal cells \[[@B40]\]. Imbalance of AsA homeostasis has also been demonstrated in neurodegenerative diseases such as AD, PD, and ALS.

In most cells, ascorbic acid is regenerated from the oxidized form of ascorbic acid, DHA \[[@B41], [@B42]\]. This recycling pathway of DHA to AsA is known to be mediated by specific reductases, such as GSH- or NADPH-dependent DHA reductases \[[@B43]--[@B45]\]. AsA is synthesized in the liver of several mammals. However, humans and other primates do not express the specific enzyme for AsA biosynthesis and are unable to synthesize AsA \[[@B46]\]. Therefore, humans require a supply of AsA from food. In this regard, understanding the mechanism for AsA recycling is important for maintaining cellular AsA homeostasis. Previous reports have shown that the DHA reductase activity of human GSTO2 is approximately 70--100-fold higher than that of human GSTO1 using an *in vitro* enzyme assay \[[@B12]\]. The notable feature of human GSTO2 is very high DHA reductase activity, which suggests that human GSTO2 may have a protective role against oxidative stress by recycling AsA \[[@B12]\]. In *Drosophila*, GstO2B has the highest GSH-dependent DHA reductase activity among the GstOs \[[@B27]\]. In addition, we showed that GSH-dependent DHA reductase activity is decreased in *GstO2* mutant flies. Furthermore, the AsA redox state, determined by the AsA/DHA ratio, was also dramatically decreased in *GstO2* mutants \[[@B39]\]. These studies suggest that GstO2B may be critical in the maintenance of AsA concentrations in cells and plays a protective role against oxidative stress by regulating the AsA recycling pathway in *Drosophila*.

4. Structural Difference and Diverse Function of Omega GSTs in *Drosophila* {#sec4}
===========================================================================

Binding of the GSH to GSTs is highly conserved in the N-terminal domain. Substrate-binding sites (H-site) in the C-terminal domain of GSTs are variable with different features, hydrophobicities, shapes, and electrostatic potential distributions \[[@B47]\]. Many research groups have shown that residues in the substrate-binding sites of omega class GST homologues are well conserved across species \[[@B48]--[@B50]\]. Although most residues in the G-site and H-site of GstOs in *Drosophila* are highly conserved \[[@B27]\], the GstOs have different physiological functions *in vivo* \[[@B39], [@B51]\]. Therefore, we constructed three-dimensional models of *Drosophila* GstOs using I-TASSER server and analyzed the surface electrostatic potential distributions ([Figure 1](#fig1){ref-type="fig"}). The electrostatic potential distributions of GstO1, GstO2A, and sepia are similar, with only some differences. In contrast, the electrostatic potential distributions of GstO2B and GstO3 differ markedly from those of the other *Drosophila* GstO electrostatic potential distributions. These features are likely to be determinants of interactions between *Drosophila* GstOs and substrates that are still to be discovered. We showed that GstOs have different electrostatic potential distributions and substrate-binding site shapes from each other, by homology modeling analysis. Because these GstO isoforms differ only in the portion of the C-terminal domain that binds the hydrophobic substrate, this region may influence substrate preference. These data may explain the functional differences between each GstO isoforms. However, the differences in the functions and catalytic mechanisms of GstOs have not been fully elucidated. Identification of the differences in the structure and electrostatic potential of the GstO substrate-binding sites helped us understand the catalytic role of GstOs in reaction with different substrates and their ability to perform different functions *in vivo*.

5. Putative Functions of Other GSTOs in *Drosophila* {#sec5}
====================================================

Although the *in vivo* function of *Drosophila* GstO3 is not yet elucidated, there is some evidence that it may also be involved in antioxidant processes. The *GstO3* transcript of *Drosophila* is expressed at approximately the same level in all tissues. Interestingly, the expression level of *GstO3* transcript increased in response to various stressors such as heat shock, heavy metal stress, and exposure to rotenone \[[@B52]--[@B54]\]. However, little is known with regard to the exact mechanism responsible for increased GstO3 expression. Thus, GstO3 may have a wide range of antioxidant activities. Further studies are required to understand the physiological function and molecular mechanism by which GstO3 protects cells from various oxidative stressors.

6. Conclusions and Perspective {#sec6}
==============================

GSTs are ubiquitously expressed enzymes belonging to the GSH-mediated antioxidant. Sequence alignment analyses revealed that GSTs, including GSTOs, exist in a wide range of organisms. The broad distribution of several GSTs among all living organisms may reflect its important and diverse physiological functions. Particularly, the role exerted by GSTOs in neuronal cells appears to be relevant. Although various studies suggest that oxidative stress plays an important role in the pathogenesis of several human diseases, including neurodegenerative diseases, the exact mechanism of GSTOs in neuroprotective effects against several oxidative stressors that provide a pharmacological basis for the relationship between GstOs and the development of neurodegenerative diseases has not been elucidated. As discussed in this review, our research on *Drosophila* GstOs has shown that GstOs are involved in protective effects against various neurotoxic conditions. For instance, GstO1 has a protective function against H~2~O~2~-induced neurotoxicity by regulating the MAPK signaling pathway. In addition, GstO2 is required for the activation of mitochondrial ATP synthase in the *Drosophila* model of PD. This finding suggests that enhancing the activity of GstO2 in neuronal cells could alleviate neurodegeneration in the *Drosophila* model of PD. Furthermore, GstO2 has a DHA reductase activity and is required for the recycling of AsA. Thus, GstO2 may play a critical role in the maintenance of AsA concentrations in neuronal cells and plays a protective role against oxidative stress by regulating the AsA recycling pathway in neuronal cells. A comprehensive understanding of various neuroprotection mechanisms of *Drosophila* GstOs and a further investigation of their pharmacological and antitoxicological properties will enhance our understanding of their role in neuronal cells and the pathogenesis of neurodegenerative diseases.

Previously, our studies provided several evidences for novel diverse roles of GstOs, based on genetic and molecular studies using the *Drosophila* model system. The C-terminal domain, including the H-site of *Drosophila* GstOs, is less similar than the N-terminal domain, which contains a cysteine residue in the G-site of GstOs. Thus, the structural differences in the C-terminal domain of GstOs may be responsible for the differences in the functions of various *Drosophila* GstOs and may influence substrate preference. Further studies are required to identify the *in vivo* substrates of GSTOs, which are related to neuroprotection, in order to better understand the functional diversity of GSTOs. Because various biological processes are conserved in *Drosophila* and mammals, we expect that the elucidation of diverse *in vivo* functions of *Drosophila* GstOs will have broad biological implications in understanding neuroprotection mechanisms.

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Education, Science and Technology (MEST) (2014R1A1A2058027; 2017R1D1A1B03035010), the Ministry of Science and ICT (MSIT) (2017R1C1B1008825; 2014R1A1A1037106), and the Soonchunhyang University Research Fund.

Conflicts of Interest
=====================

The authors declare no conflicts of interest.
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